These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
763 related items for PubMed ID: 15612981
21. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group. Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406 [Abstract] [Full Text] [Related]
24. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. Clin Transplant; 2003 Jun 27; 17(3):234-41. PubMed ID: 12780674 [Abstract] [Full Text] [Related]
26. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation. Miura M, Harada H, Fukuzawa N, Iwami D, Taniguchi A, Seki T, Togashi M, Ogawa Y, Satoh H, Hirano T. Clin Transplant; 2005 Jun 27; 19 Suppl 14():54-8. PubMed ID: 15955170 [Abstract] [Full Text] [Related]
27. Open-label, multicenter study on the safety, tolerability, and efficacy of Simulect in pediatric renal transplant recipients receiving triple therapy with cyclosporin, mycophenolate, and corticosteroids. Turconi A, Rilo LR, Goldberg J, de Boccardo G, Garsd A, Otero A. Transplant Proc; 2005 Mar 27; 37(2):672-4. PubMed ID: 15848497 [Abstract] [Full Text] [Related]
29. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens. Wlodarczyk Z, Walaszewski J, Perner F, Vitko S, Ostrowski M, Bachleda P, Kokot F, Klinger M, Szenohradszky P, Studenik P, Navratil P, Asztalos L, Rutkowski B, Kalmar KN, Hickey D. Transpl Int; 2005 Feb 27; 18(2):157-62. PubMed ID: 15691267 [Abstract] [Full Text] [Related]
30. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants. Hesse UJ, Troisi R, Jacobs B, Van Vlem B, de Hemptinne B, Van Holder R, Vermassen F, De Roose J, Lameire N. Clin Transplant; 2000 Aug 27; 14(4 Pt 1):340-4. PubMed ID: 10945205 [Abstract] [Full Text] [Related]
32. Cost-benefit of steroid avoidance in renal transplant patients: a prospective randomized study. Gheith OA, Nematalla AH, Bakr MA, Refaie A, Shokeir AA, Ghoneim MA. Scand J Urol Nephrol; 2010 Apr 27; 44(3):175-82. PubMed ID: 20230185 [Abstract] [Full Text] [Related]
33. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O. Transplantation; 2001 Jul 15; 72(1):13-21. PubMed ID: 11468528 [Abstract] [Full Text] [Related]
34. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. Demirbaş A, Tuncer M, Yavuz A, Gürkan A, Kaçar S, Cetinkaya R, Tekin S, Akbaş SH, Akaydin M, Ersoy F, Yakupoğlu G. Transplant Proc; 2004 Jul 15; 36(1):175-7. PubMed ID: 15013338 [Abstract] [Full Text] [Related]
35. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. Hoshinaga K, Aikawa A, Murai M, Yamamoto H, Hirayama N, Shishido S, Hasegawa A. Transplant Proc; 2005 May 15; 37(4):1762-3. PubMed ID: 15919457 [Abstract] [Full Text] [Related]
36. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Boillot O, Seket B, Dumortier J, Pittau G, Boucaud C, Bouffard Y, Scoazec JY. Liver Transpl; 2009 Nov 15; 15(11):1426-34. PubMed ID: 19877264 [Abstract] [Full Text] [Related]
37. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C. Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759 [Abstract] [Full Text] [Related]
38. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Ciancio G, Tryphonopoulos P, Gaynor JJ, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell RH, Ruiz P, Vianna R, Burke GW. Transplant Proc; 2016 Dec 17; 48(6):2006-10. PubMed ID: 27569936 [Abstract] [Full Text] [Related]
39. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N, Bakkaloglu A. Transplant Proc; 2003 Dec 17; 35(8):2878-80. PubMed ID: 14697926 [Abstract] [Full Text] [Related]
40. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G. Transplant Proc; 2007 Sep 17; 39(7):2163-6. PubMed ID: 17889125 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]